Lecanemab

GPTKB entity

Statements (57)
Predicate Object
gptkbp:instance_of gptkb:monoclonal_antibody
gptkbp:brand gptkb:Leqembi
gptkbp:chemical_formula C6484 H10080 N1716 O2016 S44
gptkbp:clinical_trial gptkb:Clarity_AD
Phase 3
improved cognitive function
safety profile established
multiple sites worldwide
reduced amyloid levels
gptkbp:collaboration academic institutions
research organizations
gptkbp:developed_by gptkb:Biogen
gptkb:Eisai
gptkbp:dosage_form solution for infusion
gptkbp:effective_date FDA approved
January 2023
gptkbp:funding public and private sectors
https://www.w3.org/2000/01/rdf-schema#label Lecanemab
gptkbp:indication early Alzheimer's disease
gptkbp:invention patented
gptkbp:is_tested_for Phase 1
Phase 2
gptkbp:launch_date gptkb:2023
gptkbp:marketed_as gptkb:European_Union
gptkb:Japan
gptkb:United_States
gptkbp:mechanism_of_action reduces amyloid plaques
gptkbp:patient_population older adults
individuals with early-stage Alzheimer's disease
gptkbp:provides_guidance_on Alzheimer's treatment guidelines
gptkbp:regulatory_compliance conditional approval
gptkbp:research biological therapy
gptkbp:research_areas gptkb:neurodegenerative_diseases
gptkbp:research_focus Alzheimer's disease treatment
disease-modifying therapies
biomarker development
gptkbp:route_of_administration intravenous
gptkbp:side_effect dizziness
fatigue
headache
nausea
confusion
infusion-related reactions
visual disturbances
increased risk of falls
cerebral edema
cerebral microhemorrhage
gptkbp:sponsor gptkb:Biogen
gptkb:Eisai
gptkbp:target_audience patients with mild Alzheimer's disease
patients with mild cognitive impairment
gptkbp:targets amyloid beta
gptkbp:used_for gptkb:neurodegenerative_diseases
gptkbp:weight 146 k Da
gptkbp:bfsParent gptkb:Biogen_Idec
gptkb:Aducanumab
gptkbp:bfsLayer 5